NeuBase Therapeutics (NBSE) Financials
$0.38
$0.00 (0.00%)As on 24-May-2024 09:30EDT
Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Cost of Revenue
|
0.85
|
1.26
|
0.58
|
0.28
|
0.13
|
13.90
|
|
|
|
|
|
|
Gross Profit
|
-0.85
|
-1.26
|
-0.58
|
-0.28
|
-0.13
|
-13.90
|
|
|
|
|
|
|
Operating Expenses
|
14.61
|
33.32
|
26.57
|
17.07
|
26.34
|
9.08
|
|
|
|
|
|
|
Operating Profit (EBIT)
|
-15.27
|
-33.32
|
-26.57
|
-17.07
|
-26.34
|
-13.90
|
|
|
|
|
|
|
Other Income
|
--
|
--
|
--
|
--
|
--
|
0.59
|
|
|
|
|
|
|
Profit before Tax
|
-13.73
|
-33.78
|
-25.41
|
-17.38
|
-26.96
|
-13.24
|
|
|
|
|
|
|
Provision for Tax
|
-0.97
|
0.46
|
0.26
|
-0.12
|
0.13
|
8.98
|
|
|
|
|
|
|
Profit after Tax (Net Income)
|
-14.31
|
-34.23
|
-25.67
|
-17.26
|
-27.09
|
-13.24
|
|
|
|
|
|
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Consolidated Profit
|
-8.46
|
-33.78
|
-25.41
|
-17.38
|
-26.96
|
-0.50
|
|
|
|
|
|
Liabilities ($ Mln) |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
9.14
|
23.19
|
54.07
|
31.29
|
10.03
|
10.90
|
|
|
|
|
|
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Non-Current Liabilities
|
4.83
|
5.34
|
5.90
|
1.64
|
1.60
|
0.07
|
|
|
|
|
|
|
Current Liabilities
|
4.65
|
4.17
|
4.19
|
3.15
|
2.50
|
0.72
|
|
|
|
|
|
|
Total Liabilities
|
23.27
|
32.69
|
64.17
|
34.44
|
12.53
|
11.63
|
|
|
|
|
|
Assets ($ Mln) |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
5.27
|
8.04
|
9.24
|
1.64
|
1.50
|
7.63
|
|
|
|
|
|
|
Current Assets
|
13.35
|
24.65
|
54.93
|
32.81
|
11.03
|
4.00
|
|
|
|
|
|
|
Total Assets
|
23.27
|
32.69
|
64.17
|
34.44
|
12.53
|
11.63
|
|
|
|
|
|
|
Total Debt*
|
5.34
|
6.00
|
6.54
|
0.14
|
0.12
|
0.07
|
|
|
|
|
|
|
Net Current Assets
|
8.70
|
20.48
|
50.73
|
29.66
|
8.53
|
3.27
|
|
|
|
|
|
Cashflow ($ Mln) |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-29.01
|
-18.87
|
-10.71
|
-2.85
|
-9.49
|
|
|
|
|
|
|
Cash Flow from Investing Activities
|
--
|
-0.47
|
-2.56
|
-0.72
|
-0.69
|
-0.69
|
|
|
|
|
|
|
Cash from Financing Activities
|
--
|
-0.26
|
42.34
|
33.11
|
13.60
|
-0.09
|
|
|
|
|
|
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
10.06
|
-9.05
|
|
|
|
|
|
Financials Ratios |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-6.85
|
-17.12
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Cash EPS ($)
|
--
|
-16.49
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Adjusted Book Value ($)
|
--
|
11.60
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Cash Flow per Share ($)
|
--
|
-14.51
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Free Cash Flow per Share ($)
|
--
|
-14.74
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Profitability Ratios |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-76.25
|
-55.77
|
-83.02
|
-256.43
|
-78.03
|
|
|
|
|
|
|
ROE (%)
|
-121.38
|
-88.62
|
-60.14
|
-83.54
|
-258.83
|
-78.45
|
|
|
|
|
|
|
ROA (%)
|
-47.61
|
-70.69
|
-52.06
|
-73.49
|
-224.25
|
-66.93
|
|
|
|
|
|
|
EBIT Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Net Margin (%)
|
--
|
--
|
--
|
--
|
--
|
-2,233.76
|
|
|
|
|
|
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Growth Ratios |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
EBIT Growth (%)
|
50.47
|
-25.42
|
-55.63
|
35.19
|
-519.32
|
82.22
|
|
|
|
|
|
|
Net Profit Growth (%)
|
57.67
|
-33.38
|
-48.70
|
36.28
|
-104.63
|
44.41
|
|
|
|
|
|
|
EPS Growth (%)
|
59.46
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Book Value Growth (%)
|
-73.74
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Valuation Ratios |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-0.02
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Price / Book Value
|
0.18
|
0.03
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
EV/EBITDA
|
0.19
|
0.50
|
1.79
|
1.90
|
0.39
|
1.18
|
|
|
|
|
|
|
Close Price ($)
|
0.87
|
7.90
|
72.20
|
151.80
|
99.80
|
74.00
|
|
|
|
|
|
|
High Price ($)
|
8.70
|
88.00
|
257.80
|
235.60
|
139.00
|
872.00
|
|
|
|
|
|
|
Low Price ($)
|
0.61
|
7.60
|
65.20
|
83.00
|
31.64
|
60.00
|
|
|
|
|
|
|
Market Cap ($ Cr)
|
1.42
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Solvency Ratios |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.26
|
0.12
|
0.00
|
0.01
|
0.01
|
|
|
|
|
|
|
Short term debt to equity ratio
|
0.05
|
0.03
|
0.01
|
0.00
|
0.01
|
0.01
|
|
|
|
|
|
|
Current Ratio
|
2.87
|
5.92
|
13.10
|
10.42
|
4.41
|
5.52
|
|
|
|
|
|
|
Quick Ratio
|
2.87
|
5.95
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Interest Coverage
|
-2,704.96
|
-1,385.55
|
-821.70
|
-2,220.83
|
-204.24
|
-6.37
|
|
|
|
|
|
Operating Efficiency Ratios |
TTM | Sep-22 | Sep-21 | Sep-20 | Sep-19 | Sep-18 | Sep-17 | Sep-16 | Sep-15 | Sep-14 | Sep-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Asset Turnover
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Inventory Days
|
--
|
-36.95
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Payable days
|
--
|
528.11
|
1,051.26
|
1,941.87
|
2,132.28
|
63.69
|
|
|
|
|
|
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
